MOA#1 microbiota | MASH treatment and fibrosis prevention study targeting gut microbiota in STAM mice

Today, we would like to introduce a demonstration example of a drug efficacy evaluation test of a bacterial consortium consisting of nine types of intestinal resident bacteria using STAMTM mouse (hereinafter “STAM mouse”), which was published in May 2022 in the journal Biomedicines by a research team from Belgium's MRM Health. I would like to introduce you.

A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo – PubMed (
(Pinheiro I et al., Biomedicines, 10, 1191, 2022) PMID: 35625927

Using STAM mouse, we performed forced oral administration of nine types of indigenous intestinal bacteria for 4 weeks from 5 to 9 weeks of age, resulting in a decrease in NAFLD activity score and serum CK-18 level, and an effect on liver fibrosis. They have reported that the progress will be suppressed. This report shows the progression of NAFLD activity score and liver fibrosis caused by the resident intestinal bacteria Faecalibacterium prausnitzii, Butyricicocccus pullicaecorum, Roseburia inulinivorans, Anaerostipes caccae, Roseburia inulinivorans, Akkermansia muciniphila, Phocaeicola vulgatus, Veillonella parvula, and Blautia obeum.

Intestinal microbiota is known to be involved in the development of MASH-liver cancer and is attracting attention as a drug discovery target (He LH et al, Front Microbiol., 12, 761836, 2021).

STAM mouse is a MASH-hepatoma model that exhibits dysbiosis characterized by increased Atopobium spp., Bacteroides spp., Bacteroides vulgatus, Bacteroides acidifaciens, Bacteroides uniformis, Clostridium cocleatum, Clostridium xylanolyticum and Desulfovibrio spp (Guoxiang X et al, Oncotarget, 7, 19355-19366, 2016). STAM mouse are the only MASH liver cancer models with dysbiosis that have been reported to date that reproduce the pathology of MASH liver cancer, and this model can be used to evaluate a wide range of conditions, from fatty liver to liver cancer. becomes possible. In fact, it has been reported that FMT and insulin administration suppress carcinogenesis through improving intestinal flora (Soeda K et al, Nat Commun., 14, 6584, 2023)

Are you interested in non-clinical studies targeting the intestinal flora using STAM mouse? For example, researchers who have fecal microbiota transplants, live bacterial preparations, low-molecular compounds, and supplements are eligible.


Table. List of targets for intestinal microbiota.


Please feel free to contact us if you are interested in running a study in our STAM™ model.